Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QX-4533 SAD, MAD, and Food Effect Study in Healthy Participants
NCT07678463Phase 1Recruiting
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of QX-4533 (4 arms). Primary endpoints: Number of Participants with Treatment-emergent Adverse Events at Day 23 and Number of Participants with Clinically Significant Change from Baseline in Clinical Laboratory Parameters at Day 23. Started Jul 2026; status: recruiting.
02
Drugs
QX-4533
Beyond the preview
Go deeper on NCT07678463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07678463.